ViiV/J&J’s long-acting HIV regimen finally approved in USThe FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the Share XViiV/J&J’s long-acting HIV regimen finally approved in UShttps://pharmaphorum.com/news/fda-finally-approves-viiv-jjs-long-acting-hiv-regimen/
How to make digital adoption a smooth journeyFour big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely Share XHow to make digital adoption a smooth journeyhttps://pharmaphorum.com/views-analysis-sales-marketing/digital-adoption-smooth-journey/
ViiV’s injection still suppresses HIV when taken every two months – studyGSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus Share XViiV’s injection still suppresses HIV when taken every two months – studyhttps://pharmaphorum.com/news/viivs-injection-still-suppresses-hiv-when-taken-every-two-months-study/
ViiV hails data showing switch from Truvada to two-drug HIV regimenViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors Share XViiV hails data showing switch from Truvada to two-drug HIV regimenhttps://pharmaphorum.com/news/viiv-hails-data-showing-switch-from-truvada-to-two-drug-hiv-regimen/
ViiV’s Dovato HIV pill approved in EUViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over Share XViiV’s Dovato HIV pill approved in EUhttps://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/
ViiV hopes for blockbuster with HIV drug combo approvalThe FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for Share XViiV hopes for blockbuster with HIV drug combo approvalhttps://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/
R&D round-up: Non-opioid painkiller space heats upAs the MHRA announced that it would be convening an Expert Working Group (EWG) to assess the risks Share XR&D round-up: Non-opioid painkiller space heats uphttps://pharmaphorum.com/views-and-analysis/rd-roundup-non-opioid-painkiller-space-heats-up/
Once-a-month HIV treatment sees promising phase III resultsJanssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III Share XOnce-a-month HIV treatment sees promising phase III resultshttps://pharmaphorum.com/news/once-a-month-hiv-treatment-sees-promising-phase-iii-results/
ViiV redeems voucher for fast FDA review of HIV combinationViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of Share XViiV redeems voucher for fast FDA review of HIV combinationhttps://pharmaphorum.com/news/viiv-redeems-voucher-for-fast-fda-review-of-hiv-combination/
